Description: Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Home Page: vaxart.com
170 Harbor Way
South San Francisco,
CA
94080
United States
Phone:
650 550 3500
Officers
| Name | Title |
|---|---|
| Dr. Sean N. Tucker Ph.D. | Senior VP & Chief Scientific Officer |
| Dr. James F. Cummings M.D. | Chief Medical Officer |
| Mr. Steven Lo | President, CEO & Director |
| Mr. Phillip Eric Lee | CFO, Principal Financial Officer & Principal Accounting Officer |
| Dr. Raymond D. Stapleton Jr., Ph.D. | Chief Technology Officer |
| Mr. Edward B. Berg | Senior VP & General Counsel |
| Ms. Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management |
| Dr. Rajesh Kapoor Ph.D. | Senior Vice President of Quality |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 48.5437 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8523 |
| Price-to-Sales TTM: | 8.8903 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 109 |